DFCM
EPZM

Dark Forest Capital Management’s Epizyme, Inc EPZM Stock Holding History

Dark Forest Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,512
Closed -$8K – 1892
2021
Q3 		$8K Buy
+1,512
New +$9.18K ﹤0.01% 1031

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Dark Forest Capital Management's EPZM Position: Q4 2021 in Review

Dark Forest Capital Management sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 1,512 shares — an estimated $8K sold.

Dark Forest Capital Management first reported a position in EPZM in Q3 2021 and held it in 1 quarter. The position peaked at $8K in Q3 2021. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Dark Forest Capital Management reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Dark Forest Capital Management sold 1,512 Epizyme, Inc shares in Q4 2021, an estimated $8K.
  • Dark Forest Capital Management first reported a position in Epizyme, Inc in Q3 2021 and held it in 1 quarter.
  • Dark Forest Capital Management's Epizyme, Inc position peaked at $8K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Dark Forest Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.